top of page

Fulcrum Therapeutics’ CEO discusses the clinical hold lift of the company’s SCD program.

Aug 23, 2023
1 min read

Alex Sapir explains a tweak in the clinical trial population that allowed the trial to resume.

https://vimeo.com/857155136

Recent Posts

BIO 2026: Nkarta will have key data by the end of the year from its NK cell therapy approach in a host of autoimmune conditions

BIO 2026: Nkarta will have key data by the end of the year from its NK cell therapy approach in a host of autoimmune conditions

BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes

BIO 2026: COUR Pharma last week raised a $50M series B to progress its nanoparticle approach to reprogramming the immune system to treat type 1 diabetes

BIO 2026: Enveda's AI discovery platform leans heavy on chemistry and learnings from Mother Nature - the lead clinical program to come out of it is focused on atopic derm

BIO 2026: Enveda's AI discovery platform leans heavy on chemistry and learnings from Mother Nature - the lead clinical program to come out of it is focused on atopic derm

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page